University Of California San Francisco

An analysis of prostate cancer trends in California revealed an unexpected spike in distant-stage disease cases between 2011 and 2021.

Ulipristal acetate followed by misoprostol was effective and acceptable for medication abortion up to 63 days’ gestation with no serious adverse events, but more studies are needed, data from a proof-of-concept study show.

A new error grid to assess the accuracy of glucose measurements could give continuous glucose monitor manufacturers and regulatory agencies such as the FDA a better understanding of how accurate their devices are.

National support for expanded medication abortion access, including advance provision and over-the-counter availability, rose since the Dobbs decision, particularly among women residing in abortion-restrictive states, survey data show.

Heterosexual midlife women veterans reported more sexual dysfunction and impact from vaginal symptoms and were less likely to be sexually active compared with sexual minority counterparts, according to findings published in Menopause.

Laura J. van ’t Veer, PhD, will receive the William L. McGuire Memorial Lecture Award at this year’s San Antonio Breast Cancer Symposium, scheduled for Dec. 10-13.

SAN DIEGO — Eltrombopag conferred a higher rate of durable platelet response in the absence of rescue treatments than standard first-line treatments for children with newly diagnosed immune thrombocytopenia, according to study results.

WASHINGTON — Biosimilar infliximab use is significantly more common among new users vs. those who started with the originator, and particularly less likely among Medicare beneficiaries, according to data presented at ACR Convergence 2024.

Black and multiracial children with systemic lupus erythematosus demonstrate higher disease activity and are less likely to achieve low disease activity compared with white children, according to data published in Arthritis Care & Research.

A research study, WISDOM, is currently underway to improve breast cancer diagnosis timing and outcomes by comparing annual mammography with a personalized screening approach to identify women at highest risk for fast-growing cancers.